We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01676259
Recruitment Status : Recruiting
First Posted : August 30, 2012
Last Update Posted : July 2, 2021
Information provided by (Responsible Party):
Silenseed Ltd

Tracking Information
First Submitted Date  ICMJE August 28, 2012
First Posted Date  ICMJE August 30, 2012
Last Update Posted Date July 2, 2021
Actual Study Start Date  ICMJE March 7, 2018
Estimated Primary Completion Date October 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 30, 2021)
ORR at 6 months [ Time Frame: One year ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 29, 2012)
Progression-free survival (PFS) in the study population [ Time Frame: One year ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
Official Title  ICMJE A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
Brief Summary

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment.

Primary Outcome:

- ORR at 6 months.

Detailed Description

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable LAPC combined with chemotherapy treatment (Gemcitabine+nab-Paclitaxel or Folfirinox or modified Folfirinox). This will be a study to assess the response rate of the siG12D-LODER in patients with unresectable or borderline resectable LAPC. The study is of a single arm design with one arm receiving siG12D-LODER + chemotherapy.

The investigational agent siG12D-LODER is a miniature biodegradable bio polymeric matrix that encompasses the drug, designed and produced by Silenseed Ltd. The implantation of LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.

siG12D-LODER has been studied in the escalating dose Phase I study of 15 patients, and results showed high safety and tolerability profiles, with no single DLT.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer
Intervention  ICMJE
  • Drug: siG12D-LODER
    The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
  • Drug: Gemcitabine+nab-Paclitaxel
    Other Name: Chemotherapy
  • Drug: Folfirinox
    Folfirinox or modified Folfirinox
    Other Name: Chemotherapy
Study Arms  ICMJE Experimental: siG12D-LODER + chemotherapy
Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
  • Drug: siG12D-LODER
  • Drug: Gemcitabine+nab-Paclitaxel
  • Drug: Folfirinox
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 18, 2016)
Original Estimated Enrollment  ICMJE
 (submitted: August 29, 2012)
Estimated Study Completion Date  ICMJE August 2023
Estimated Primary Completion Date October 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:


1. Subject must be 18 years of age or older at the time of signing the informed consent.

Type of Subject and Disease Characteristics

  1. Histologically or cytologically confirmed adenocarcinoma of the pancreas.
  2. Locally advanced pancreatic cancer stage III according to The American Joint Committee on Cancer (AJCC) and defined as T4, N (any) and M0, according to the three factors, T (tumor), N (node involvement), and M (metastases), of the National Comprehensive Cancer Network TNM classification.
  3. Allocated to receive one of the following chemotherapies: gemcitabine plus nab-paclitaxel, FOLFIRINOX or modified FOLFIRIONOX as first line treatment for pancreatic cancer.
  4. Have a target tumor that is accessible for intratumoral administration by EUS as determined by the radiologist/gastroenterologist performing the EUS intratumoral administration, according to The American Society for Gastrointestinal Endoscopy (ASGE) guidelines (https://www.asge.org/home/practice-support/guidelines).
  5. Have measurable disease. Subject will have a histologically-confirmed disease and must have clinically and/or radiographically documented measurable primary disease according to RECIST v1.1. At least one site of disease must be unidimensionally measurable.

    Diagnostic Assessments

  6. Eastern Cooperative Oncology Group (ECOG) Performance Scale of ≤ 1.
  7. Demonstrate adequate organ function as defined below:

    • serum creatinine <1.6 mg/dL
    • international normalized ratio (INR) < 1.5 U
    • absolute neutrophil count (ANC) > 1.5 x 109/L
    • platelets ≥ 100 x 109/L
    • hemoglobin ≥ 9 mg/dL
    • alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 5 times upper limit of normal (ULN)
    • bilirubin ≤ 1.5 x ULN Sex
  8. Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  9. Women of childbearing potential (WOCBP): a negative serum or urine pregnancy test during screening.
  10. Subject of childbearing potential, if sexually active (both men and women) must agree to use a barrier method of contraception, from the time of administration of the first treatment and for at least 8 weeks after EOT visit day.

    Informed Consent

  11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria apply:

Medical Conditions

  1. Subjects with resectable pancreatic cancer.
  2. Evidence of metastatic disease.
  3. Other malignancy that would interfere with the current intervention.
  4. Any evidence of ascites (beyond trace).
  5. Bulky celiac adenopathy (≥2.5 cm) or non-adenocarcinoma histology.
  6. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers from which the subject has been disease-free for at least 2 years.
  7. History of clinically significant coagulopathy.
  8. Major surgery, other than diagnostic surgery, within 4 weeks prior to study entry without complete recovery.
  9. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 4 months prior to the first chemotherapy cycle Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease.
  10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  11. Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.
  12. Females who are pregnant or breast-feeding.
  13. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.

    Prior/Concomitant Therapy

  14. Any prior therapy for the treatment of pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational).
  15. Prior therapy with any hypoxic cytotoxic agent (hypoxia-targeting drugs). Prior/Concurrent Clinical Study Experience
  16. Subjects who are participating or participated in an investigational drug or device study (within 28 days prior to study entry from the last study dose date).

    Other Exclusions:

  17. Unwillingness or inability to comply with the study protocol for any reason.
  18. Known allergy to sesame oil.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Orit Pollack-Shragai, MSc, MBA +972-52-8466267 orit@silenseed.com
Listed Location Countries  ICMJE Israel,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01676259
Other Study ID Numbers  ICMJE SLSG12D-P2
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Silenseed Ltd
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Silenseed Ltd
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Eileen M O'Reilly, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Talia Golan, MD Sheba Medical Center
PRS Account Silenseed Ltd
Verification Date June 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP